Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516925) titled 'A Study of Ivonescimab in People With Leiomyosarcoma' on April 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Leiomyosarcoma
Intervention:
Drug: Ivonescimab
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: April 1, 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07516925
Published by HT Digital Content Services with permiss...